DE60233133D1 - Polymorphe formen von 1-ä4-(5-cyanoindol-3-yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid - Google Patents

Polymorphe formen von 1-ä4-(5-cyanoindol-3-yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid

Info

Publication number
DE60233133D1
DE60233133D1 DE60233133T DE60233133T DE60233133D1 DE 60233133 D1 DE60233133 D1 DE 60233133D1 DE 60233133 T DE60233133 T DE 60233133T DE 60233133 T DE60233133 T DE 60233133T DE 60233133 D1 DE60233133 D1 DE 60233133D1
Authority
DE
Germany
Prior art keywords
butylu
carbamoylbenzofuran
cyanoindol
polymorphic forms
piperazine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233133T
Other languages
English (en)
Inventor
Andreas Bathe
Bernd Helfert
Steffen Neuenfeld
Heike Kniel
Matthias Bartels
Susanne Rudolph
Henning Boettcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60233133(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of DE60233133D1 publication Critical patent/DE60233133D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
DE60233133T 2001-06-19 2002-06-05 Polymorphe formen von 1-ä4-(5-cyanoindol-3-yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid Expired - Lifetime DE60233133D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113647 2001-06-19
PCT/EP2002/006153 WO2002102794A2 (en) 2001-06-19 2002-06-05 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride

Publications (1)

Publication Number Publication Date
DE60233133D1 true DE60233133D1 (de) 2009-09-10

Family

ID=8177643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233133T Expired - Lifetime DE60233133D1 (de) 2001-06-19 2002-06-05 Polymorphe formen von 1-ä4-(5-cyanoindol-3-yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid

Country Status (30)

Country Link
US (15) US7381726B2 (de)
EP (1) EP1397357B9 (de)
JP (3) JP4624667B2 (de)
KR (1) KR20040012922A (de)
CN (2) CN100384841C (de)
AR (1) AR034595A1 (de)
AT (1) ATE437871T1 (de)
AU (1) AU2002320822B2 (de)
BR (1) BR0210495A (de)
CA (16) CA2782519A1 (de)
CY (1) CY1109447T1 (de)
CZ (2) CZ305220B6 (de)
DE (1) DE60233133D1 (de)
DK (1) DK1397357T3 (de)
EC (1) ECSP044943A (de)
EE (1) EE05454B1 (de)
ES (1) ES2330314T3 (de)
HK (2) HK1066003A1 (de)
HU (1) HU229601B1 (de)
IL (2) IL159426A0 (de)
MX (1) MXPA03011723A (de)
MY (1) MY151087A (de)
NZ (1) NZ530642A (de)
PL (1) PL208708B1 (de)
PT (1) PT1397357E (de)
RU (1) RU2303598C2 (de)
SK (2) SK288334B6 (de)
UA (1) UA76758C2 (de)
WO (1) WO2002102794A2 (de)
ZA (1) ZA200400329B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
US9708300B2 (en) 2011-03-20 2017-07-18 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102219783B (zh) * 2011-05-05 2013-07-03 天津市汉康医药生物技术有限公司 盐酸维拉佐酮及其组合物
US9505744B2 (en) 2011-11-23 2016-11-29 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
CA2859106A1 (en) 2011-12-12 2013-06-20 Ranbaxy Laboratories Limited Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
US9969721B2 (en) 2012-04-12 2018-05-15 Alembic Pharmaceuticals Limited Process for the preparation of vilazodone hydrochloride and its amorphous form
WO2013156935A1 (en) * 2012-04-16 2013-10-24 Ranbaxy Laboratories Limited Process for the preparation of crystalline vilazodone hydrochloride
WO2013164794A1 (en) * 2012-05-04 2013-11-07 Ranbaxy Laboratories Limited Crystalline forms of vilazodone hydrochloride
WO2013168126A1 (en) * 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
WO2013175361A1 (en) 2012-05-24 2013-11-28 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
CN102702180A (zh) * 2012-05-25 2012-10-03 吉林三善恩科技开发有限公司 一种维拉佐酮有机药物共晶及其制备方法
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
WO2013182946A2 (en) 2012-06-06 2013-12-12 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
WO2013185209A1 (en) * 2012-06-13 2013-12-19 Apotex Technologies Inc. Forms of vilazodone and processes for the preparation thereof
WO2014028473A1 (en) 2012-08-13 2014-02-20 Assia Chemical Industries Ltd. New salts of vilazodone and solid state forms thereof
WO2014049609A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Novel salts of vilazodone
WO2014049612A2 (en) * 2012-09-27 2014-04-03 Msn Laboratories Limited Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN103772368B (zh) * 2012-10-24 2016-08-03 杭州和泽医药科技有限公司 盐酸维拉佐酮iv晶型的制备方法及其应用
CN103772367B (zh) * 2012-10-24 2016-05-25 杭州和泽医药科技有限公司 盐酸维拉佐酮v晶型的制备方法及其应用
WO2014087428A1 (en) * 2012-12-07 2014-06-12 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of vilazodone and intermediates thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
WO2014178013A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Vilazodone impurities, process for their preparation, and their use as reference standards
IN2013MU02001A (de) 2013-06-12 2015-05-29 Lupin Ltd
EP2824104A1 (de) 2013-07-12 2015-01-14 Sandoz AG Verfahren zur Herstellung von Form III von Vilazodonhydrochlorid
WO2015019237A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone
WO2015019256A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone and processes of preparation thereof
WO2015037010A1 (en) * 2013-09-13 2015-03-19 Symed Labs Limited Preparation of vilazodone hydrochloride crystalline form iv
CN104610238A (zh) * 2013-11-01 2015-05-13 北京英科博雅科技有限公司 一种维拉佐酮盐酸盐iii晶型新的制备方法
ITMI20131839A1 (it) * 2013-11-06 2015-05-07 Dipharma Francis Srl Co-cristallo di un farmaco antidepressivo
WO2015102019A2 (en) * 2013-12-30 2015-07-09 Msn Laboratories Private Limited Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride
CN105017233A (zh) * 2014-04-23 2015-11-04 天津药物研究院 一种盐酸维拉佐酮晶体、其制备方法、药物组合物和用途
CN105820157B (zh) * 2015-01-09 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸维拉佐酮晶型及其制备方法
CN106518854A (zh) * 2016-09-21 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸维拉佐酮晶型ⅳ的制备方法
TR201702104A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇lazodon hi̇droklorür farmasöti̇k bi̇leşi̇mleri̇
TR201702103A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vilazodon hi̇droklorürün tablet formlari
CN107098889A (zh) * 2017-03-17 2017-08-29 北京万全德众医药生物技术有限公司 盐酸维拉佐酮药物晶型ⅲ的制备方法
CN109503560A (zh) * 2017-09-14 2019-03-22 北京万全德众医药生物技术有限公司 盐酸维拉佐酮ⅺ晶型的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532241A (en) * 1895-01-08 Computing-machine
US1294526A (en) * 1917-09-21 1919-02-18 Gerhard Nicolaas Vis Manufacture of sodium carbonate and ammonium sulfate from bisulfate of soda.
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5521241A (en) * 1994-08-30 1996-05-28 W. R. Grace & Co.-Conn. Styrene copolymer-based plastisol containing glycidyl methacrylate
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
KR20030053502A (ko) 2000-07-13 2003-06-28 하이드로겐 에너지 아메리카 엘엘씨 물의 해리에 의한 수소 발생을 제어하기 위한 방법 및 장치
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
US7384020B2 (en) * 2006-06-30 2008-06-10 Amtek System Co., Ltd. Supporting frame structure

Also Published As

Publication number Publication date
DK1397357T3 (da) 2009-10-05
IL159426A (en) 2011-12-29
US7834020B2 (en) 2010-11-16
US20110183994A1 (en) 2011-07-28
CN101139345B (zh) 2012-07-11
UA76758C2 (uk) 2006-09-15
US7981894B2 (en) 2011-07-19
US20110190317A1 (en) 2011-08-04
CA2782521A1 (en) 2002-12-27
AR034595A1 (es) 2004-03-03
US7381726B2 (en) 2008-06-03
IL159426A0 (en) 2004-06-01
US20110294825A1 (en) 2011-12-01
CZ200426A3 (cs) 2004-04-14
CA2782515A1 (en) 2002-12-27
RU2303598C2 (ru) 2007-07-27
EP1397357B1 (de) 2009-07-29
CA2451028A1 (en) 2002-12-27
CA2782857A1 (en) 2002-12-27
EE05454B1 (et) 2011-08-15
AU2002320822B2 (en) 2007-11-15
PL364576A1 (en) 2004-12-13
CA2782862A1 (en) 2002-12-27
CA2782628A1 (en) 2002-12-27
US20040147528A1 (en) 2004-07-29
MXPA03011723A (es) 2004-03-19
ECSP044943A (es) 2004-02-26
US20090023749A1 (en) 2009-01-22
PL208708B1 (pl) 2011-05-31
HUP0400236A3 (en) 2010-06-28
US8673921B2 (en) 2014-03-18
EP1397357B9 (de) 2009-11-18
CN101139345A (zh) 2008-03-12
CA2683040A1 (en) 2002-12-27
HU229601B1 (en) 2014-02-28
HUP0400236A2 (hu) 2004-06-28
US20190343831A1 (en) 2019-11-14
BR0210495A (pt) 2004-08-17
JP2004534803A (ja) 2004-11-18
US8236804B2 (en) 2012-08-07
US20140024658A1 (en) 2014-01-23
MY151087A (en) 2014-04-15
CA2451028C (en) 2012-07-17
ZA200400329B (en) 2005-06-29
RU2004100824A (ru) 2005-06-20
CZ304471B6 (cs) 2014-05-21
US8318744B2 (en) 2012-11-27
US20110312971A1 (en) 2011-12-22
JP2010132688A (ja) 2010-06-17
US8921375B2 (en) 2014-12-30
CA2782615A1 (en) 2002-12-27
CA2782761A1 (en) 2002-12-27
NZ530642A (en) 2006-09-29
JP5411734B2 (ja) 2014-02-12
JP5714824B2 (ja) 2015-05-07
CA2782623A1 (en) 2002-12-27
US8927552B2 (en) 2015-01-06
SK162004A3 (en) 2004-04-06
WO2002102794A2 (en) 2002-12-27
US20130102616A1 (en) 2013-04-25
US20110294824A1 (en) 2011-12-01
EP1397357A2 (de) 2004-03-17
CA2782494A1 (en) 2002-12-27
CN1516699A (zh) 2004-07-28
CA2782868A1 (en) 2002-12-27
ES2330314T3 (es) 2009-12-09
CA2782517A1 (en) 2002-12-27
HK1116165A1 (de) 2008-12-19
EE200400019A (et) 2004-04-15
US9624204B2 (en) 2017-04-18
CA2782519A1 (en) 2002-12-27
CY1109447T1 (el) 2014-08-13
US20170182037A1 (en) 2017-06-29
CA2782791A1 (en) 2002-12-27
CZ305220B6 (cs) 2015-06-17
JP4624667B2 (ja) 2011-02-02
CA2782865A1 (en) 2002-12-27
ATE437871T1 (de) 2009-08-15
SK288334B6 (sk) 2016-02-02
US8193195B2 (en) 2012-06-05
CN100384841C (zh) 2008-04-30
PT1397357E (pt) 2009-11-03
KR20040012922A (ko) 2004-02-11
US20210251986A1 (en) 2021-08-19
SK288162B6 (sk) 2014-03-04
JP2010132687A (ja) 2010-06-17
US20140275115A1 (en) 2014-09-18
US20100016332A1 (en) 2010-01-21
CA2683040C (en) 2012-09-25
WO2002102794A3 (en) 2003-02-20
HK1066003A1 (en) 2005-03-11
US20150080411A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
DE60233133D1 (de) Polymorphe formen von 1-ä4-(5-cyanoindol-3-yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid
DE60236226D1 (de) Verbesserung der Altersweitsichtigkeit
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE60310592D1 (de) Geneigte schraubenfedern verschiedener ausführung
DK1472255T3 (da) Aza-arylpiperaziner
NO20043079L (no) Piperazinderivat
DE60233399D1 (de) Erzerrung zweiter ordnung
DK1370553T3 (da) Rho-kinase-inhibitorer
DK1370552T3 (da) Rho-kinase-inhibitorer
NO20020307L (no) N-(indolkarbonyl)-piperazinderivater
DE02784674T1 (de) Quantifizierung von polypeptiden
ATE391502T1 (de) Kristalline formen von fluvastatin-natrium
DE60238571D1 (de) Mannich-Detergens aus sekundärem Amin
DE50209888D1 (de) Druckverfahren
NO20041449L (no) Krystallinformer av valasyklovir-hydroklorid
ATE329177T1 (de) Reibungsdämpfendes bein
ITMI20011726A0 (it) Forme polimorfe della lercanidipina cloridrato
DE50200615D1 (de) Geminitenside
ITMI20021834A1 (it) Sospensione di apparecchiature
ATE477803T1 (de) Metabolit von quetiapine
DE60310413D1 (de) Luftfederbalg
DE50107986D1 (de) Luftfederbalg
DE50200250D1 (de) Geminitenside
DE60217089D1 (de) Lipidsenkende biphenylcarbonsäureamide
ATE369339T1 (de) Pseudopolymorphe formen von carvedilol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition